Works matching IS 03407004 AND DT 2010 AND VI 59 AND IP 4
Results: 15
Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 609, doi. 10.1007/s00262-009-0788-2
- By:
- Publication type:
- Article
FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release.
- Published in:
- Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 575, doi. 10.1007/s00262-009-0775-7
- By:
- Publication type:
- Article
Type I interferons inhibit the generation of tumor-associated macrophages.
- Published in:
- Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 587, doi. 10.1007/s00262-009-0776-6
- By:
- Publication type:
- Article
Homeostasis of peripheral FoxP3<sup>+</sup> CD4<sup>+</sup> regulatory T cells in patients with early and late stage breast cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 599, doi. 10.1007/s00262-009-0780-x
- By:
- Publication type:
- Article
Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 529, doi. 10.1007/s00262-009-0769-5
- By:
- Publication type:
- Article
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-α for metastatic renal cell cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 553, doi. 10.1007/s00262-009-0773-9
- By:
- Publication type:
- Article
Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties.
- Published in:
- Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 563, doi. 10.1007/s00262-009-0774-8
- By:
- Publication type:
- Article
A B-cell lymphoma vaccine using a depot formulation of interleukin-2 induces potent antitumor immunity despite increased numbers of intratumoral regulatory T cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 519, doi. 10.1007/s00262-009-0768-6
- By:
- Publication type:
- Article
CD4<sup>+</sup>CD45RA<sup>+</sup>CXCR4<sup>+</sup> lymphocytes are inversely associated with progression in stages I–III melanoma patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 511, doi. 10.1007/s00262-009-0766-8
- By:
- Publication type:
- Article
Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model.
- Published in:
- Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 541, doi. 10.1007/s00262-009-0771-y
- By:
- Publication type:
- Article
Effective adoptive therapy of tap-deficient lymphoma using diverse high avidity alloreactive T cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 629, doi. 10.1007/s00262-009-0805-5
- By:
- Publication type:
- Article
Regulation of immunity and oncogenesis by the IRF transcription factor family.
- Published in:
- Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 489, doi. 10.1007/s00262-009-0804-6
- By:
- Publication type:
- Article
Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program.
- Published in:
- Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 619, doi. 10.1007/s00262-009-0814-4
- By:
- Publication type:
- Article
Erratum to: A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo.
- Published in:
- 2010
- By:
- Publication type:
- Correction Notice
ESCII–PIVAC meeting “Recent advances in cancer immunotherapy with an emphasis on cancer vaccines” held in Athens, 9–11 October 2008.
- Published in:
- Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 635, doi. 10.1007/s00262-009-0664-0
- By:
- Publication type:
- Article